Supporting evidence
Semaglutide × BMI
- Authoritative support
- 4
- Available studies
- 4
- Unavailable support
- 0
Available supporting studies
Study 1 · Limited
GLP-1 agonists reduce heart fat thickness in diabetes.
- Comparison
- Patients received semaglutide as part of their treatment regimen. · Patients received dulaglutide as part of their treatment regimen. · Patients received metformin as the control treatment.
- Duration / follow-up
- 12 weeks
Study 2 · Included
Novel Semaglutide Injection Shows Non-Inferior Glycemic Control
Rct
- Comparison
- Patients received once weekly semaglutide injection for 24 weeks. · Patients received reference semaglutide injection for 24 weeks.
- Duration / follow-up
- 24 weeks
Relevant effects
Absolute change
4.59
Absolute change
1.76
Study 3 · Included
Oral semaglutide reduces cardiovascular events in type 2 diabetes
Rct
- Comparison
- Participants receiving oral semaglutide as an adjunct to standard of care treatment. · Participants receiving placebo treatment.
- Duration / follow-up
- 208 weeks
Relevant effect
Absolute change
1.5 · 0.05
Study 4 · Limited
Semaglutide improves liver health and lipid levels in diabetes
- Comparison
- Patients received oral semaglutide with a starting dose of 3 mg daily and an up titration to 14 mg for 48 weeks. · Patients received sc injectable semaglutide starting with 0.25 mg weekly for 4 weeks and up titration to 2 mg weekly for 48 weeks. · Patients received pioglitazone and/or vitamin E.
- Duration / follow-up
- 52 weeks
Relevant effects
Absolute change
3.14 · 0.001
Absolute change
5.32 · 0.001
Absolute change
0.98 · 0.03